Medtronic wins expanded FDA approval for diabetic-friendly Resolute Integrity stent

February 25, 2013 by Arezu Sarvestani

U.S. healthcare regulators approved new sizes of Medtronic's Resolute Integrity drug-eluting stent to treat longer coronary lesions.

Medtronic's Resolute Integrity stent

Medical device giant Medtronic (NYSE:MDT) won expanded FDA approval for new sizes of its Resolute Integrity drug-eluting stent, the only devices of its kind with regulatory indication for treatment in patients with diabetes.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp